Results 81 to 90 of about 4,843 (156)

Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia

open access: yes
International audienceImportance Many pediatric patients with heterozygous familial hypercholesterolemia (HeFH) cannot reach recommended low-density lipoprotein cholesterol (LDL-C) concentrations on statins alone and require adjunct lipid-lowering ...
Manvelian, Garen   +9 more
core   +1 more source

Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundNon‐high‐density lipoprotein cholesterol (non‐HDL‐C) and apolipoprotein (apo) B are better predictors of atherosclerotic cardiovascular disease risk than low‐density lipoprotein cholesterol alone.
Harold E. Bays   +6 more
doaj   +1 more source

Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

open access: yes, 2019
BACKGROUND Patients with acute coronary syndrome (ACS) and history of coronary artery bypass grafting (CABG) are at high risk for recurrent cardiovascular events and death.OBJECTIVES This study sought to determine the clinical benefit of adding ...
Chumburidze, Vakhtang   +495 more
core   +2 more sources

Time to achieve target lipid metabolism parameters and its impact on long-term outcomes after acute coronary syndrome in conditions of multicomponent lipid-lowering therapy

open access: yesТерапевтический архив
Aim. To evaluate the effect of the initiation time of lipid-lowering therapy (LLT) with the use of the proprotein convertase subtilisin/kexin type 9 (iPCSK9) inhibitor alirocumab on the incidence of adverse outcomes during 18-month follow-up after acute ...
Aleksei A. Nekrasov   +5 more
doaj   +1 more source

The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab[S]

open access: yesJournal of Lipid Research, 2017
An elevated level of lipoprotein (a) [Lp(a)] is a risk factor for CVD. Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9, is reported to reduce Lp(a) levels.
Byambaa Enkhmaa   +5 more
doaj   +1 more source

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin

open access: yes, 2014
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in phase 3 clinical development.
Hoek, A.M. van den   +10 more
core  

Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses [PDF]

open access: yes, 2019
BACKGROUND: Alirocumab is a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9). OBJECTIVE: Changes in PCSK9, alirocumab, and low-density lipoprotein cholesterol (LDL-C) levels were assessed after treatment with alirocumab at ...
DiCioccio, A Thomas   +18 more
core   +1 more source

Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis

open access: yesMedicina
Background and Objectives: The proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab are recently developed promising drugs used for treatment of familial hypercholesterolemia (FH).
Guoguang Xiao   +4 more
doaj   +1 more source

Protective effect of alirocumab, a PCSK9 inhibitor, on the sciatic nerve of rats with diabetic peripheral neuropathy

open access: yesEndocrine Journal
Dyslipidemia has been considered a risk factor for diabetic peripheral neuropathy. Proprotein convertase subtilisin-like/Kexin 9 inhibitor (PCSK9) inhibitors are a new type of lipid-lowering drug currently in clinical use.
Na Cui   +6 more
doaj   +1 more source

Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background In this post hoc analysis of the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial, we evaluated the efficacy of alirocumab in patients with probable heterozygous ...
Gregory P. Geba   +14 more
doaj   +1 more source

Home - About - Disclaimer - Privacy